Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma

Nat Rev Clin Oncol. 2015 Nov;12(11):625-6. doi: 10.1038/nrclinonc.2015.170. Epub 2015 Sep 29.

Authors

Ryan J Sullivan¹, Keith T Flaherty¹

Affiliation

¹ Department of Medicine, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA.

PMID: 26416151
DOI: 10.1038/nrclinonc.2015.170

No abstract available

Publication types

News

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
Clinical Trials, Phase II as Topic
Disease-Free Survival
Humans
Immunotherapy
Melanoma / drug therapy*
Melanoma / mortality
Melanoma / pathology
Neoplasm Metastasis
Randomized Controlled Trials as Topic

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
pembrolizumab